1-4 of 4
Satoshi Konagai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression

Hiroaki Tanaka, Hideki Sakagami, Naoki Kaneko, Satoshi Konagai, Hiroko Yamamoto, Takahiro Matsuya, Masatoshi Yuri, Yosuke Yamanaka, Masamichi Mori, Masahiro Takeuchi, Hiroyuki Koshio, Masaaki Hirano, Sadao Kuromitsu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (8): 1366–1373.
https://doi.org/10.1158/1535-7163.MCT-18-0976
Published: 01 August 2019
View article titled, Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
Open the PDF for Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression in another window
Includes: Supplementary data
Journal Articles

Abstract B188: Preclinical antitumor activity of ASP8273, a mutant-selective irreversible EGFR inhibitor in an AXL-overexpressing NSCLC model

Naoki Kaneko, Hiroaki Tanaka, Satoshi Konagai, Hiroko Yamamoto, Hideki Sakagami, Tomohiro Eguchi, Takahiro Matsuya, Masamichi Mori, Hiroyuki Koshio, Tadashi Terasaka, Masaaki Hirano, Sadao Kuromitsu, Masahiro Takeuchi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B188.
https://doi.org/10.1158/1535-7163.TARG-15-B188
Published: 01 December 2015
View article titled, Abstract B188: Preclinical antitumor activity of ASP8273, a mutant-selective irreversible EGFR inhibitor in an AXL-overexpressing NSCLC model
Journal Articles

The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice

Masamichi Mori, Yoko Ueno, Satoshi Konagai, Hiroshi Fushiki, Itsuro Shimada, Yutaka Kondoh, Rika Saito, Kenichi Mori, Nobuaki Shindou, Takatoshi Soga, Hideki Sakagami, Takashi Furutani, Hitoshi Doihara, Masafumi Kudoh, Sadao Kuromitsu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 329–340.
https://doi.org/10.1158/1535-7163.MCT-13-0395
Published: 09 February 2014
View article titled, The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Open the PDF for The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice in another window
Includes: Supplementary data
Journal Articles

Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models.

Sadao Kuromitsu, Masamichi Mori, Itsuo Shimada, Yutaka Kondoh, Nobuaki Shindoh, Takatoshi Soga, Takashi Furutani, Satoshi Konagai, Hideki Sakagami, Mari Nakata, Yoko Ueno, Hiroshi Fushiki, Rika Saito, Masao Sasamata, Hiroyuki Mano, Masafumi Kudou
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A227.
https://doi.org/10.1158/1535-7163.TARG-11-A227
Published: 12 November 2011
View article titled, Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models.